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A B S T R A C T
An impairment of the endothelial barrier function underlies a wide spectrum of pathological conditions. Hered-
itary angioedema due to C1-inhibitor deficiency (C1-INH-HAE) can be considered the “pathophysiological and
clinical paradigm” of Paroxysmal Permeability Diseases (PPDs), conditions characterized by recurrent transient
primitively functional alteration of the endothelial sieving properties, not due to inflammatory-ischemic-degener-
ative injury and completely reversible after the acute flare. It is a rare yet probably still underdiagnosed disease
which presents with localized, non-pitting swelling of the skin and submucosal tissues of the upper respiratory
and gastrointestinal tracts, without significant wheals or pruritus. The present review addresses the pathophys-
iology of C1-INH-HAE with a focus on the crucial role of the endothelium during contact and kallikrein/kinin
system (CAS and KKS) activation, currently available and emerging biomarkers, methods applied to get new in-
sights into the mechanisms underlying the disease (2D, 3D and in vivo systems), new promising investigation
techniques (autonomic nervous system analysis, capillaroscopy, flow-mediated dilation method, non-invasive fin-
ger plethysmography). Hints are given to the binding of C1-INH to endothelial cells. Finally, crucial issues as the
local vs systemic nature of CAS/KKS activation, the episodic nature of attacks vs constant C1-INH deficiency, pros
and cons as well as future perspectives of available methodologies are briefly discussed.
1. Introduction
1.1. The complexity of the vascular endothelium
Nowadays it is recognized that the vascular endothelium is not only
a passive physical barrier that separates blood from the surrounding tis-
sues: it is actually an active player, able to continuously and dynami-
cally regulate pivotal cardiovascular functions.
Remarkably, in response to shear stress, changes of the chemical en-
vironment, fluctuations in the concentration of vasoactive agents, en-
dothelial cells can process multiple and even contradictory messages,
coordinating all the inputs to produce an efficient response. This is the
result of the heterogeneity of endothelial cells thanks to which the en-
dothelium may be considered as a complex organ, whose properties ex-
ceed those of single cells [1].
Through the release of a variety of mediators (e.g. nitric oxide,
prostacyclins, endothelin, superoxide and thromboxane) endothe
lial cells modulate vasodilation and vasoconstriction, with a net impact
on blood flow and blood pressure [2]. The blood clotting cascade, fibri-
nolysis and platelet activation are regulated by endothelial factors [3],
as is also angiogenesis [4].
A fine tuning of endothelial permeability is crucial for complex
processes as inflammation and immune response [5]. Significant effort
has been done to deepen our knowledge on the processes induced by
inflammatory agonists/immune mediators to promote generation of in-
tercellular gaps, leading to leukocyte diapedesis, increased delivery of
molecules and circulating substances across the endothelial barrier.
While passage of fluids from the intravascular to the interstitial space
occurs via diffusion and filtration, the passage of proteins and macro-
molecules is regulated by interendothelial junctions (paracellular path-
way) [6] or biochemical transporters, fenestrae and vescicular trans-
port systems (transcellular pathway) [7]. Among specialized selective
junctional systems (mainly adherens junctions and tight junctions), a
pivotal role is played by Vascular endothelial cadherin (VE-cadherin,
also known as CD144), whose phosphorylation and internalization (in
⁎ Corresponding author at: Department of Biomedical and Clinical Sciences, ASST Fatebenefratelli Sacco, University of Milan, via Giovanni Battista Grassi 74, 20157 Milan, Italy.
E-mail address: wu.maddalena@asst-fbf-sacco.it (M.A. Wu)
https://doi.org/10.1016/j.intimp.2020.106304
Received 12 August 2019; Accepted 10 Febraury 2020
Available online xxx
1567-5769/© 2020.
UN
CO
RR
EC
TE
D
PR
OO
F
M.A. Wu et al. International Immunopharmacology xxx (xxxx) xxx-xxx
duced by mediators as histamine and vascular endothelial growth fac-
tor) is responsible for alterations of the endothelial sieving properties
[8,9].
The subsequent defects in endothelial permeability can lead to
edema and increase in interstitial pressure, which in turn can induce
compression and altered tissue perfusion.
An impairment of the endothelial barrier function underlies a wide
spectrum of pathological conditions. Alterations of the endothelial mor-
phology and function (thickening of the intima, proliferation of smooth
muscle cells, formation of the fibrous plaque, changes of the vasa vaso-
rum, loss of endothelium-derived nitric oxide, hyper-adhesiveness of the
vascular lining toward platelets) are at the basis of the processes leading
to atherosclerosis, which is responsible for coronary, cerebral, periph-
eral artery and aortic diseases.
Over time, the term “endothelial dysfunction” has been used with
reference to the loss of endothelium's ability to regulate vascular resis-
tance. Therefore, this alteration might imply effective chronic structural
changes of the endothelial cell barrier (as in pulmonary hypertension
and neurodegenerative disorders) or also conditions characterized by a
transient alteration of endothelial morphology and function, which is re-
stored almost to normal after the resolution of the acute phase. Among
the latter conditions is sepsis, which is characterized by endothelial dys-
function due above all to functional changes (increased leukocyte ad-
hesion and trafficking, altered vasomotor tone, loss of barrier function,
shifts in hemostatic balance and programmed cell death), even though
endothelial structural changes can also occur (nuclear vacuolization, cy-
toplasmic swelling, cytoplasmic fragmentation, denudation, and/or de-
tachment).
However, nowadays it is clear that it is possible to identify also a va-
riety of diseases, the so-called Paroxysmal Permeability Diseases (PPDs)
[10], which are due to or exacerbated by recurrent alteration of en-
dothelial permeability, with no inflammatory, degenerative, ischemic
vascular injury and with complete restitutio ad integrum after each parox-
ysmal alteration. Among these conditions are different forms of pri-
mary angioedema (hereditary/acquired angioedema due to C1 inhibitor
deficiency, idiopathic histaminergic and non-histamnergic angioedema,
hereditary angioedema with normal C1 inhibitor), Idiopathic Systemic
Capillary Leak Syndrome and other yet poorly defined forms of periodic
edema (e.g. recurrent retroperitoneal edema, Gleich’s syndrome) [10].
The clinical condition which serves as “pathophysiological and clin-
ical paradigm” of this nosological entity is undoubtedly hereditary an-
gioedema due to C1-inhibitor deficiency (C1-INH-HAE).
1.2. Hereditary angioedema
1.2.1. Angioedema with and without wheals
Angioedema is a localized self-limiting swelling with variable etiol-
ogy. It can arise with wheals in the setting of allergic reactions or ur-
ticaria (either acute or chronic, spontaneous or inducible) as a result of
mast cell degranulation. Angioedema without wheals can still be medi-
ated by histamine, but can also be independent of mast cells and in this
event it stands as a separate entity and can be inherited or acquired.
In 2014 a comprehensive classification of “angioedema without
wheals” was elaborated, identifying three types of hereditary an-
gioedema (genetic C1-INH deficiency, normal C1-INH with Factor XII
mutations and unknown origin) and four types of acquired angioedema
(due to C1-INH deficiency, related to ACE inhibitors intake, idiopathic
histaminergic and idiopathic non-histaminergic) [11].
C1-INH-HAE is an autosomal dominant disorder due to mutations in
one of the two alleles of SERPING1, the gene coding for C1-INH, located
on chromosome 11q12–q13.1. The gene consists of eight exons distrib-
uted over 17 kb, with introns containing repetitive Alu sequences
[12]. About 500 different mutations causing C1-INH-HAE have been de-
scribed so far (http://www.hgmd.cf.ac.uk).
Phenotypic effects of these mutations are quantitative (C1-INH-HAE
type I, 85% of cases) or functional (C1-INH-HAE type II, 15% of the
cases) deficiencies in C1-INH [13].
C1-INH-HAE has a prevalence which ranges from 1:50,000 to
1:100,000 throughout the world [14]. Acquired C1 inhibitor deficiency:
(C1-INH AAE) is about 10 times rarer and commonly associated with
lymphoproliferative diseases [15].
Nowadays new mutations underlying the pathogenesis of some more
challenging forms of angioedema keep being discovered, as a mutation
in the angiopoietin 1 gene [16], in the plasminogen gene [17] and in
the kininogen gene [18].
Due to marked heterogeneity of clinical presentations and to lack of
straightforward genotype-phenotype correlation, comprehensive knowl-
edge of angioedema phenotypes is crucial for a correct diagnosis and for
choosing the appropriate therapeutic approach [19].
Among hereditary angioedema, the best characterized form is due to
C1 inhibitor deficiency (C1-INH-HAE), which is the focus of the present
review.
1.2.2. The clinical picture of hereditary angioedema due to C1 inhibitor
deficiency (C1-INH-HAE)
Clinically, C1-INH-HAE is characterized by localized, non-pitting
edema of the skin and submucosal tissues of the upper respiratory and
gastrointestinal tracts, without significant wheals or pruritus, due to a
temporary increase in vascular permeability. Attacks involving the up-
per airways can be rapidly fatal leading to asphyxia, while abdomi-
nal crises can be so painful that they can mimic surgical emergencies
[11,19].
In C1-INH-HAE, angioedema has slow progression, with an increase
during the first 12–36 h and complete remission in 2–4 days.
In the first accurate description of angioedema, Quincke observed
that “acute circumscribed edema of the skin” (then entitled: “angioneu-
rotic”) could occur with and without urticaria. Three centuries earlier,
Marcello Donati (De medica historia mirabili libri, Mantua) described a
boy presenting with wheals (rash) on the face and angioedema of the
lips after eating eggs. In 1888 Osler presented the full clinical picture
and the familial nature of hereditary angioedema (HAE) [20]. These
three seminal descriptions already contain the critical issues that should
be considered when dealing with angioedema.
The overall burden of chronically recurrent angioedema is remark-
able, due to personal-domestic-social and occupational disability and to
exposure to the risk of death (when the respiratory tract is involved lead-
ing to asphyxia) [11,13]. Along with the limitations related to acute
attacks, patients experience substantial impairment also in between at-
tacks due to the fear for upcoming ones [21].
2. Pathophysiology of C1-INH-HAE
2.1. The contact activation system (CAS) and kallikrein/kinin system (KKS)
After the detailed description of the clinical picture of hereditary an-
gioedema by Osler (1888) [20], it took about 75 years until a group of
researchers headed by Dr. Virginia Donaldson (1963) [22] shed light
on the central role of C1 inhibitor in the pathophysiology of HAE. This
seminal discovery paved the way to the work of many subsequent re-
searchers who gave their contribution to the understanding of the com-
plex pathogenetic pathways underlying this clinical condition, allowing
to test and design more and more “targeted” therapies [23].
C1-INH belongs to the superfamily of serine protease inhibitors (SER-
PIN) that all together constitute 20% of the plasma proteins [24,25].
It is a glycoprotein of 478 amino acid residues encoded by the SER-
PING1 gene on chromosome 11 [26]. It regulates several serine pro-
teases of the clotting, fibrinolytic, complement and kinin sys
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tems and is the only known physiologic inhibitor of C1r and C1s [27].
Thus, edema associated with C1-INH deficiency has been previously
considered as the result of an uncontrolled activation of the comple-
ment system, with release of a kinin from C2 [28]. It is now proved that
the swellings characterizing C1-INH-HAE primarily involve activation
of the contact system and kinin-forming pathway [29,30]. These path-
ways move from activated factor XII (FXIIa) and plasma kallikrein (PK),
both controlled by C1-INH, with cleavage of high molecular weight
kininogen (HK) and final release of the nonapeptide bradykinin (BK)
[31]. Bradykinin binds specific B2 receptors (B2Rs), which are G-pro-
tein-coupled receptors that activate the nitric oxide (NO) pathway,
causes prostacyclin production, uncoupling of endothelial cell junc-
tions, thus enhancing endothelial permeability and eventually causing
edema [32,33]. B2Rs are are ubiquitous and constitutively expressed;
in inflammatory conditions, the bradykinin B1 receptor (B1R), another
G-protein-coupled receptor, may be expressed, further increase of vas-
cular permeability. B1R has no affinity for BK, but better recognizes
des-Arg9-BK originating from the C-terminal truncation of BK by car-
boxypeptidase M or N.
Moreover, nowadays we know that there are 2 major kinin-generat-
ing proteases: plasma kallikrein and tissue kallikrein (KLK-1). The lat-
ter is considered to have protective action on cardiovascular and renal
functions [34]. KLK-1 produces primarily Lys-BK from low molecular
weight kininogen, which is equipotent with BK at the human B2 recep-
tor, but KLK-1 has never been associated to HAE. On the other hand, be-
ing Lys-des-Arg9-BK the only natural kinin sequence with a subnanomo-
lar affinity for B1R, this suggests that the tissue kallikrein-kinin system
and B1R may be strongly integrated [35].
Selective blockade of B2R with icatibant is an effective treatment for
angioedema attacks and it improves outcomes [34]. Contrary to B2R,
the involvement of B1R in HAE is still elusive.
Remarkably, even though the terms ‘kallikrein/kinin system’ (KKS)
and ‘contact activation system’
(CAS) are often erroneously used as synonyms and despite undeni-
able overlap between the two systems, it is of pivotal importance to un-
derline that the activation of the KKS (with subsequent release of BK)
may be independent of activation of CAS, since PK can be activated in
both a FXIIa-dependent and a FXIIa-independent manner [36]. Besides
FXIIa, other recognized activators of prekallikrein are prolylcarboxypep-
tidase (PRCP) [37] and heat shock protein 90 (Hsp90) [38].
Most of plasma prekallikrein (about 85%) circulates in complex with
HK, through which it is recruited to the surface of endothelial cells.
Indeed, through its domains 3 and 5, HK interacts with cytokeratin 1
(CK1), C1q receptor (gC1qR) and urokinase plasminogen activator re-
ceptor (uPAR) to form a multiprotein receptor complex on endothelial
surface [39,40]. Also FXIIa can directly bind to endothelial cells surface
through the same multiprotein assembly, but not necessary to the same
binding sites as HK [41].
The precise mechanism/s by which initiation of kallikrein-kinin
forming cascade occurs on the endothelial cell surface is still subtle.
Activation of plasma occurs upon incubation with human umbilical
vein endothelial cells. Zinc-dependent binding of plasma proteins to the
above-described multiprotein assembly is a requisite for activation to
take place. In vitro data support both factor XII-dependent and factor
XII-independent mechanisms; the latter require a cell-derived protease
to activate prekallikrein and the presence of HK and zinc ions [42].
Recent research has also allowed to unravel that contact and plas-
minogen activation system are strictly functionally coupled and that not
only FXIIa can act as plasminogen activator, but also plasmin can act as
FXII activator [43].
The abnormal hyperactivation of CAS/KKS, with increased produc-
tion of BK from HK mediated by PK, is currently considered the main
trigger of the attacks.
Indeed, the first obvious treatment strategy used was the replace-
ment of the deficient protein with C1 inhibitor concentrate. Afterwards,
evidence of the efficacy of icatibant served as further confirmation that
the constitutively expressed bradykinin B2 receptor plays a key role in
HAE pathogenesis [33].
Recent evidence shows that inflammatory mechanisms (eg, heparin
released from allergen-activated mast cells) can initiate formation of
bradykinin and its breakdown metabolites (some of which, such as
Des-Arg BK, are still active mediators of angioedema) and that regu-
lation of the bradykinin B2 receptors (and possibly also B1 receptors)
plays a crucial role in bradykinin-induced vascular hyperpermeability
[44,45]. However, as above mentioned, concerning the role of B1 re-
ceptors in humans, caution is required when translating results of exper-
imental studies to clinical situations.
Since the lack of C1- INH as well as its reduced activity is constant,
as shown by the low levels of the complement component 4 (C4) which
is a biochemical alteration found in the large majority of patients [11],
the observation that attacks are recurrent and patients are completely
asymptomatic during intercritical phases is intriguing and challenging.
The direct implication is the presence of inducible cofactors, which can
have a role to determine the onset and development of acute attacks
(most of which are unpredictable, even if acute infections, traumas and
psychological stress are often reported as triggers). The role of cofactors
has also been hypothesized to explain the reasons why the disease is
characterized by an intrinsic high unpredictability (timing and features
of attack recurrences), both among affected family members and in the
very same patient throughout different periods of life.
As BK activity is directed on endothelial cells, which in turn are re-
sponsible for the leakage of plasma in the interstitial space and for the
angioedema formation, understanding the activity and the function of
endothelial cells in this setting is of paramount importance.
Current knowledge about endothelial cells in C1-INH-HAE is the aim
of this review.
2.2. The endothelium during angioedema attacks
2.2.1. The crucial role of endothelium during contact – kallikrein/kinin
system activation
The endothelium has a crucial role in triggering angioedema attacks,
through local CAS/KKS system activation. In fact, Factor XII, the leading
activator of the contact system, is located on the vessel walls after the
exposition of a binding site. The actual receptor is still matter of debate:
negative charged molecules have been proposed by Hofman et al. be-
cause they promptly activate the enzyme in vitro (for example, kaolin or
dextran sulfate) [46], while, as above-mentioned, other Authors suggest
a role for a protein receptor, namely urokinase plasminogen activator
receptor (u-PAR) and cytokeratin-1 (CK-1) complex [47].
Either way, autoactivation of Factor XII activates PK, which in turn
proteolyzes HK and releases BK, which exerts its paracrine activity
through the B2R exposed on the endothelial cells themselves. Contact
system activation has the potential to spread systemically due to the ac-
tivated soluble form of Factor XII (ß-FXIIa) [46].
The underlying mechanisms, which boost the onset of the process in
a certain area rather than in another one and the reasons why the reac-
tions tend to occur locally rather than spreading systemically have not
been elucidated yet. However, a local priming of the endothelial cells
could be hypothesized, allowing to explain also the reasons why some-
times an attack involves different not adjacent sites at the same time.
The binding of C1-INH to activated endothelial cells has been shown
[48–51]. Notwithstanding, the influence of this binding on C1-INH
regulatory activity of complement and contact systems remains con-
troversial. Plasma kallikrein has been shown to be relatively
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less susceptible to inhibition by C1-INH when bound to endothelial cells
[52].
First of all, the C1-INH binding partner on the endothelial surface
has not been identified yet and could vary in different situations. It has
been proven that pdC1-INH binds with low affinity to P- and E-selectin
adhesion molecules expressed on the endothelial cell surface in the early
stages of inflammation. Indeed, Kajdácsi et al. demonstrated that en-
dothelial cells are activated during HAE attacks in C1-INH deficient pa-
tients and that soluble E-selectin was significantly increased in patients’
plasma [53]. In this context, the binding of C1-INH to selectin mole-
cules on the endothelial surface may serve to localize and concentrate
C1-INH at these sites, which would result in more efficient local inhibi-
tion of activation of the complement and contact systems.
On the other hand, recent studies suggest a previously unrecognized
involvement of the ficolins and mannose-associated serine proteases
(MASPs) in the pathophysiology of C1-INH-HAE [54–58]. Evaluation
of the lectin pathway of complement during attack and symptoms free
periods suggested an activation of the ficolin-lectin pathway during at-
tacks [57]. In particular, the serum levels of mannose-associated serine
protease 1 (MASP-1) and its complex formation with C1-INH have been
linked to the severity of C1-INH-HAE [58].
Additionally, a new mechanism of bradykinin production by MASP-1
was demonstrated, independent from factor XII and kallikrein. Def-
initely, MASP-1 could contribute to a yet unrecognized effect on
bradykinin levels in C1-INH-HAE patients [59].
C1-INH binding to endothelial cells, both via ficolins or lectins, is
mediated by the carbohydrate linked to the molecule, especially in its
N-terminal domain. The impact of C1-INH glycosylation on C1-INH
binding to endothelial cells waits to be addressed.
2.2.2. The search for a biomarker
C1-INH-HAE is characterized by the unpredictable nature of attacks,
that sometimes can be elicited by known triggers, but more often affect
the patients unexpectedly. Frequency, severity and location of attacks
deeply differ from patient to patient and, even in the same patient, they
may change throughout the course of life. The severity of the clinical
phenotype strongly influences the burden of the disease and patients’
quality of life.
Besides the correct diagnosis of C1-INH-HAE, which has clear and
worldwide accepted criteria, the identification of disease-specific bio-
markers that could reflect disease activity and response to therapy still
remains an open question. Some clinical conditions can be confusing
also for patients with firm C1-INH-HAE diagnosis. For example, abdom-
inal attacks in C1-INH-HAE patients sometimes mimic acute surgical ab-
domen (whereas C1-INH-HAE patients can also suffer from abdominal
pain of different etiology as in the general population); until now the
response to therapy is fundamental to distinguish these clinical entities;
an acute attack biomarker could be useful to unravel these complex sit-
uations.
Although C1-INH and C4 are crucial diagnostic biomarkers, they can-
not be measured in all hospital settings on a routine basis, and never
in emergency settings, so results are usually available a few days or
weeks later. In 2016 Bork et al. showed that shortened activated par-
tial thromboplastin time (aPTT) may help to diagnose C1-INH-HAE and
C1-INH-AAE when other tests are not available, above all in emergency
setting [60]. aPTT is a routine and easy screening test for the intrinsic
and common pathways of plasmatic blood coagulation. Elevated plasma
levels of D-dimer, a marker of fibrin degradation, have been found in
C1-INH-HAE patients both in symptom-free period and during acute at-
tacks [61]. aPTT and D-dimer are easily available in hospital settings,
and also in emergency, but they are both not specific for angioedema, so
probably not useful in the daily routine.
The search of ideal biomarkers is a very difficult task. Kaplan and
Maas have outlined in a recently published review the fundamen
tal characteristics of a molecule to be named a biomarker [62]. It is not
just a molecule whose quantity or activity correlates with a disease fea-
ture, but it also needs to help with patients’ management in a practi-
cal way. Therefore, it needs to be taken from an easily accessible sam-
ple type like blood and have a long half-life in blood. Moreover, the
available assays are requested to have a minimum set of properties; they
have to be specific and sensitive, robust, rapid, affordable and sustain-
able from an economic point of view.
Half-life is a fundamental point that has hampered the scientists to
use bradykinin as a biomarker; it is an obvious potential one for its
pathobiologic link to disease mechanisms, but its half-life is too short
and its dosage is technically challenging. In order to circumvent this ob-
stacle, Suffritti et al. have tried and succeeded in finding a surrogate
of BK that could be used as biomarker. In 2014 they have shown that
cleaved high-molecular-weight kininogen (cHK), produced by the cleav-
age of BK from HK, correlates with disease states in C1-INH-HAE [63].
cHK plasmatic levels are lower in patients with unfrequent attacks (<12
attacks/year). Its practical utility has been recently proved in a clinical
trial, in which the Western blot assay measuring cHK has been used in
order to evaluate the pharmacodynamic profile of lanadelumab, a mon-
oclonal antibody inhibitor of kallikrein. This assay has numerous prac-
tical limitations that have been possibly overcome by an immune-assay
for cHK detection using a monoclonal antibody ELISA method developed
in 2017 by Hofman et al [64].
Even though they are far from being used in practical life, there are
many proposals for new biomarkers, and the most promising sources ap-
pear to be the components of plasma contact system, endothelial cell-re-
lated and inflammatory factors. We will focus on endothelium-derived
and vasoactive mediators, in line with the topic of this review.
Since BK tends to be increased in plasma of C1-INH-HAE patients,
as shown by the evidences exposed of HK consumption even during re-
mission phase [63], a homeostasis-preserving mechanism could be hy-
pothesized, leading to enhanced vasoconstriction and increased release
of anti-permeability factors in plasma of C1-INH-HAE patients, in or-
der to counteract BK activity. Surprisingly, as explained into details in
the following paragraph, vascular endothelial growth factors (VEGF-A,
VEGF-C), Angiopoietin 1 (Angpt1) and 2 (Angpt2), adrenomedullin and
phospholipase A2 (PLA2), all known to drive vasodilation and permeabi-
lization, were found to be increased in intercritical phases [65–68].
VEGF-A and VEGF-C are expressed in a broad variety of tissues, in-
cluding endothelial cells, in response to tissue hypoxia. Their plasma
levels are higher in patients during intercritical phase than in normal
controls; moreover, they are significantly higher in patients with more
frequent attacks, suggesting a pathogenetic role as predisposing factors
[65]. Plasma concentrations of VEGF-A and VEGF-C are not altered dur-
ing attack compared to remission [69].
Angpt2, a proangiogenic factor involved in endothelial homeostasis,
mainly produced by endothelial cells, shows a similar pattern in remis-
sion phase, being higher in C1-INH- HAE patients and, among them, in
those with more frequent attacks [65].
Angpt2, as well as the vascular endothelial-protein tyrosine phos-
phatase (VE-PTP), is a negative regulator of the tyrosine kinase recep-
tor Tie2, which is located predominantly on vascular endothelial cells
and plays a central role in vascular stability. In fact, Angpt2 counteracts
the stabilizing effects of Angpt1: Angpt1 is able to activate Tie2 induc-
ing its autophosphorylation, leading to the activation of downstream sig-
naling pathways that stabilize the endothelium and guarantee cell juc-
tion integrity; on the opposite, Angpt2 inactivates Tie2, destabilizing the
vasculature and making endothelial cells more responsive to the effects
of VEGF and other inflammatory cytokines, thus increasing endothelial
permeability [70].
The Angpt2/ Angpt1 ratio was decreased during angioedema at-
tacks; in fact, concentrations of Angpt1 were increased during at
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tacks compared to symptoms-free periods, whereas Angpt2 levels were
not altered [69].
The recent identification of a missense mutation in the angiopoi-
etin 1 gene (ANGPT1, c.807G > T, p.A119S) in a family with previously
“unknown HAE” has highlighted that in these patients a reduction of
Angpt1 multimeric forms leads to reduced ability to bind the Tie2 recep-
tor, with the result of increased vascular leakage [16]. This discovery
draws possible links between apparently separated types of hereditary
angioedema, highlighting once more the complexity of the systems in-
volved and the likely cross-talks between different mediators and signal-
ing pathways.
Blood endothelial cells and vascular permeability can be modulated
by the PLA2 superfamily, including secreted PLA2 (sPLA2) and platelet
activating factor acetylhydrolase (PAF-AH). We have recently described
that plasma levels of sPLA2 group 2A (PLA2G2A) and PAF-AH are al-
tered in C1-INH-HAE patients during symptom-free periods compared to
healthy donors [68]. Differences between patients with a high vs low
frequency of attacks for PAF-AH but not for sPLA2 activity were found.
We also demonstrated that both sPLA2 and PAF-AH activity are reduced
during attacks if compared with the basal condition [69]. Therefore,
they could be potential biomarkers to distinguish the acute attack phase
from the remission period.
Differently from the above-mentioned mediators, levels of endothe-
lin-1 and arginine vasopressin, peptides derived respectively from en-
dothelium and hypothalamus, both of which show vasoconstrictor activ-
ity, were found to be not different in C1-INH-HAE as compared to the
normal control [66]. During an acute HAE attack endothelin-1 and argi-
nine vasopressin increase and could theoretically have a role to counter-
balance BK activity [66]; adrenomedullin, broadly expressed peptide,
has vasodilatory activity but counteracts the BK-driven vasopermeabi-
lization, and is found elevated as well during attacks [66].
Another mediator that deserves some attention is nitric oxide (NO),
a vasoactive molecule, which is physiologically released by the endothe-
lium through the endothelial nitric oxide synthase (eNOS). It is remark-
able that eNOS activity is regulated by many proteins, among which
Hsp90, thus supporting the hypothesis that eNOS activity might be al-
tered in case Hsp90 is released after endothelial activation. Demirtuk et
al. observed that eNOS plasma levels are increased in C1-INH-HAE pa-
tients both in remission and during attacks, and eNOS metabolites are
elevated during attacks period [71]. This may reflect a sustained hyper-
permeability state in C1-INH-HAE patients, and make this pathway a po-
tential source of biomarkers, even if further studies are needed.
Adhesion molecules VE-cadherin, Endocan and vascular cell adhe-
sion molecule 1 (VCAM-1) were showed to be increased in C1-INH-HAE
patients, so representing potential biomarkers [72,73].
Finally, both von Willebrand factor antigen (vWf antigen) and col-
lagen binding activity (vWfcb activity), important co-factor involved in
coagulation process, have been shown to be increased in C1-INH HAE
patients.
Recent observations show that levels of oxidative products of metab-
olism (ROS) are lower in controls than in C1-INH-HAE and FXII-HAE
patients and that ROS are higher in C1-INH-HAE subjects than in FXII
subjects [74].
In Table 1 a summary of mediators is shown, with indications about
their biological role together with changes observed in C1-INH-HAE pa-
tients both during remission and acute attack.
Fig. 1 highlights the crucial role of the endothelium in C1-INH-HAE
pathophysiology.
3. In vitro methods to get insights into the mechanisms underlying
CL-INH-HAE
Endothelial cell monolayers are a good in vitro model to study dif-
ferent aspects of vascular leakage [75]. When forming a mono
layer, cultured endothelial cells are connected to each other by cell junc-
tions (such as adherens, tight, and gap junctions) which are essential to
ensure vascular integrity and to control permeability. Vasopermeabiliz-
ing factors, such as BK, can induce cytoskeleton modification and forma-
tion of paracellular gaps that can be studied in vitro.
3.1. Two dimensional systems
Traditionally, two experimental approaches are used to assess vascu-
lar permeability in endothelial cell culture: diffusion of labeled macro-
molecules through a cell monolayer grown on a porous filter (transwell
permeability assays) and measurements of transendothelial electrical re-
sistance (TEER) by impedance of cell monolayers [75].
Both methods offer some advantages but presents also some limita-
tions concerning sensitivity, time and spatial resolution and feasibility
[76].
Impedance measurements allow monitoring of changes in the
cell-monolayer in real time and are ideally suited to study time courses;
moreover, they provide a high sensitivity. However, this technique, be-
sides being expensive, has a limited spatial resolution due to the size
of the electrodes used. Furthermore, permeability is evaluated indirectly
and does not allow identification of the real cause for the change in im-
pedance that may be due to changes in cell-cell contacts, but may also
be caused by other factors, such as altered ion currents, cell adherence
to the microelectrodes or cell membrane permeability.
Transwell assay have the advantage to allow assessment of the size
selectivity of intercellular barriers as different size (from 4 to 150 kDa)
of labeled macromolecule can be employed as macromolecular tracers.
The choice of the proper tracer molecules is critical, molecules foreign
to the system under study should be preferred as otherwise cell activa-
tion or transcytosis cannot be excluded. Limitation of this approach are
its low sensitivity, delayed time between measurements, need for ab-
solute coverage of the transwell membrane by cell monolayer, to avoid
unspecific leakage, and dependence of the support used (different mate-
rial and pore size) that can alter cell adhesion to the substratum.
The main drawback of both methods is that none allows for spatial
resolution of local changes in endothelial permeability, an important as-
pect to study HAE mechanism in vitro. Moreover, both assays are unable
to evaluate permeability in endothelial monolayer grown on 3D sub-
strates and exposed to shear stress, a key feature of bradykinin-induced
leakage in HAE.
More recently, a third method was developed to bypass these limita-
tions. This method is called eXpress Permeability Testing (XPerT) assay
and allows both visualization and rapid quantification of trans-mono-
layer permeability. This assay takes advantage on high affinity interac-
tions of a FITC-conjugated avidin, added in the culture medium, to the
biotinylated extracellular matrix (gelatin or collagen) immobilized on
the bottom of culture vessels [77].
Very few works are present directly assessing permeability in the
C1-INH-HAE context through in vitro and in vivo models of vascular
leakage.
Bossi et al used a transwell model system to investigate the effect
on vascular permeability induced by plasma samples obtained from pa-
tients with C1-INH deficiency [44]. They showed that attack phase
plasma (APL) induced vascular leakage, whereas remission plasma
(RPL) elicited a modest effect. The plasma permeabilizing effect was de-
layed compared to the rapid effect of bradykinin and was prevented
by blocking the gC1q receptor–high-molecular-weight kininogen inter-
action, as well as by a combination of B2 and B1 receptors antagonists,
while was partially inhibited by using an antagonist at a time. They
conclude that, additionally to the already recognized B2 receptor, both
B1 receptor and gC1q receptor are involved in the vascular leakage in-
duced by plasma from patients affected by hereditary and acquired an-
gioedema due to C1 inhibitor deficiency. Since the role of B1R in C1-
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Table 1
Summary of biomarkers discussed in the review, listed in alphabetical order. ↑: increased in comparison with healthy controls; ↓: reduced in comparison with healthy controls; = : un-
changed in comparison with healthy controls; ↓↓: reduced during attacks in comparison with remission phase; ↑↑: increased during attacks in comparison with remission phase; * : reduced
during acute attacks in comparison with the remission phase, no comparison between acute attack and healthy control available; ADMA: asymmetric dimethylarginine; aPTT: activated
partial thromboplastin time; C1-INH: C1-inhibitor; HK: High molecular weight kininogen; E-selectin: endothelial selectin; eNOS: endothelial nitric oxide synthetase MASP: mannose-bind-
ing lectin-associated serine protease; MASP-1/C1-INHc: MASP-1/C1-INH complexes; PAF-AH: platelet activating factor acetylhydrolase; ROS: reactive oxygen species; sPLA2: secreted
phospholipases A2; sPLA2G2A: secreted phospholipases A2 group IIA; unk: unknown; VCAM: Vascular cell adhesion molecule; VE-cadherin: vascular endothelial cadherin; VEGF: vascular
endothelial growth factor; vWf: von Willebrand factor; vWfcb: von Willebrand factor collagen binding.
Biomarker Biological role
C1-INH-HAE patients
remission phase
C1-INH-HAE patients
acute attack
Correlation with attack
frequency References
ADMA Nitric oxide synthase inhibitor ↑ unk unk [90]
Adrenomedullin Mediator of vasodilation, endothelial barrier
stabilization
= ↑ unk [66]
Angiopoietin 1 Mediator of endothelial barrier stabilization ↑ ↑↑ none [65,69]
Angiopoietin 2 Mediator of inflammation, angiogenesis ↑ ↑ positive [65,69]
aPTT In vitro coagulation assessment ↓ unk unk [60]
C1-INH Plasma protease inhibitor ↓ ↓↓ none [63]
C4 Complement component ↓ ↓↓ negative [63]
Cleaved HK Contact system component ↑ ↑↑ positive [63]
D-dimer Fibrinolysis product ↑ ↑ unk [61]
Endocan (soluble
form)
Intercellular adhesion molecule ↑ unk unk [72]
Endothelin 1 Mediator of vasoconstriction = ↑ unk [66]
eNOS Nitric oxide synthase ↑ ↑ unk [71]
eNOS metabolites Nitric oxide degradation products = ↑ unk [71]
E-selectin (soluble
form)
Intercellular adhesion molecule ↑ ↑ unk [53]
MASP-1 Complement component ↓ unk negative [58,59,78]
MASP-1/C1-INHc Complement activation product ↓ unk negative [58,59,78]
PAF-AH Platelet activating factor (PAF) inactivator ↑ * positive [69]
ROS Oxidative products of metabolism ↑ unk unk [74]
sPLA2 activity Phospholipide digestion – functional assay ↑ * none [68]
sPLA2G2A Plasma phospholipidase ↑ * none [68]
Arginine vasopressin Mediator of vasoconstriction, renal water
reabsorption
= ↑ unk [66]
VCAM-1 (soluble
form)
Intercellular adhesion molecule ↑ unk unk [72]
VE-cadherin (soluble
form)
Intercellular adhesion molecule = ↑ unk [73]
VEGF-A Mediator of inflammation, angiogenesis ↑ ↑ positive [65,69]
VEGF-C Mediator of lymphangiogenesis ↑ ↑ positive [65,69]
vWf antigen Factor VIII stabilization = ↑ unk [53]
vWfcb activity vWf – functional assay = ↑ unk [53]
INH-HAE patients is still controversial and multiple pathways have been
proposed to generate BK-related peptides from blood, the use of specific
activators and/or inhibitory agents would have been precious to high-
light the molecular mechanism underlying the reported observations.
The in vitro results were confirmed through in vivo experiments in
male Wistar Kyoto rats. The permeability of mesenteric vessels to fluo-
rescein isothiocyanate labelled bovine serum albumin (FITC-BSA) after
topical administration of either APL or RPL was analyzed by intravital
microscopy. APL caused extravasation of FITC-BSA, whereas RPL failed
to induce vascular leakage. FITC-BSA leakage was totally abrogated by
reperfusion with a mixture of the B1R and B2R antagonists before the
addition of APL.
Debreczeni et al. chose alternative in vitro models of vascular leak-
age to investigate the effect of MASP-1 on endothelial permeability.
They showed that MASP-1 has potent permeability increasing effects;
real-time micro electric sensing revealed that MASP-1 decreases the
impedance of HUVEC monolayers and XperT assay demonstrated a
MASP-1 dose-dependent increase of endothelial paracellular transport.
Moreover, they showed that the molecular mechanisms underlying this
phenomenon comprise protease activated receptor-1 mediated intracel-
lular Ca2+-mobilization, Rho-kinase activation dependent myosin light
chain (MLC) phosphorylation, cytoskeletal actin rearrangement, and
disrup
tion of interendothelial junctions. Finally, using a whole-transcriptome
microarray they show that MASP-1 significantly altered the expression
of 25 permeability-related genes, among which the most important is
the up-regulation of bradykinin receptor B2R. They therefore speculated
that MASP-1 may play a role in the pathomechanism of diseases, where
edema formation and complement lectin pathway activation are simul-
taneously present; raising the possibility that MASP-1 may be a promis-
ing target of anti-edema drug development [78]. However, further ex-
periments are needed to clarify the exact role of MASP-1 in generating
kining physiologically and in HAE.
3.2. Three dimensional systems
Recently, much work has been devoted to design novel microfluidic
three dimensional devices, which enable to culture endothelial cells and
to study the endothelial barrier function under dynamic physiological
flow conditions.
Some of these systems constitute really powerful tools, which al-
low to tightly control the fluidodynamic – mechanical and chemical mi-
croenvironment.
In order to study alterations of endothelial cells’ permeability we de-
signed the “microvasculatures-on-a-chip”, an in vitro model that mimics
important features of microvessel networks [79].
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Fig. 1. Representation of the crucial role of the vascular endothelium in the pathogenesis of hereditary angioedema due to C1 inhibitor deficiency (C1-INH-HAE). The endothelium is
continuously exposed and responds to hemodynamic stimuli (shear stress) and signals from both surrounding tissues and flowing blood, which can have an impact on the mechanisms
required for barrier maintenance and stabilization. Under resting conditions, endothelial barrier function is maintained thanks to transmembrane adhesion proteins such as VE-cadherin
at adherens junctions and claudin at tight junctions, anchored to the cortical actin cytoskeleton as well as by the glycocalyx surface layer (not shown). A variety of factors (including
trauma, stress, hormonal changes, intense physical effort) can be triggers of acute C1-INH-HAE attacks. The activation of the contact and kallikrein/kinin systems on the endothelial cell
surface moves from activated factor XII (FXIIa) and plasma kallikrein, with cleavage of high molecular weight kininogen (HK) and final release of the nonapeptide bradykinin (BK). BK
binds specific G-protein-coupled receptors, the main of which is the B2 receptor, which is a constitutively expressed receptor, generating vasodilator mediators as nitric oxide (NO) and
prostacyclin (PGI2), inducing phosphorylation of the interendothelial junction VE-cadherin and its associated catenins resulting in internalization and degradation of VE-cadherin with
destabilization of the barrier and contraction of the actomyosin cytoskeleton. This cascade leads to enhanced endothelial permeability, passage of fluids from the intravascular to the
extravascular space and subsequent edema formation. VE-cadherin phosphorylation may occur not only in response to a wide spectrum of mediators (including VEGF), but also through
inhibition of associated phosphatases (eg the phosphatase VE-PTP). BK can also bind the Bradykinin B1 receptor, which is an inducible receptor expressed during acute flares. Besides
BK, other mediators are implicated in C1-INH-HAE angioedema. VEGFs and angiopoietins may induce a state of ‘vascular preconditioning’ that can predispose to angioedema attacks.
Angiopoietin 2 (Angpt2) counteracts the stabilizing effects of Angiopoietin-1 (Angpt1); it inactivates Tie2, destabilizing the vasculature and making endothelial cells more responsive to the
effects of VEGF. VE-PTP dephosphorylates Tie2 further limiting Tie2 signaling. Proteolytic activities are shown with green arrows (dashed lines depict putative secondary pathways); steps
inhibited by C1 inhibitor and newer treatments (ecallantide, icatibant, and lanadelumab) are indicated with red T-bars. Intracellular pathways are briefly indicated. HK, high molecular
weight kininogen; BK, bradykinin; ANGPT1, angiopoietin 1; ANGPT2, angiopoietin 2; C1-INH, C1 esterase inhibitor; Factor XIIa, activated Factor XII; TIE2, tunica interna endothelial cell
kinase 2; VEGF, vascular endothelial growth factor; VEGFR, vascular endothelial growth factor receptor; PLC, phospholipase C; DAG, diacylglycerol; Ca2+, calcium; PLA2, phospholipase
A2; PGI2, prostacyclin; eNOS, endothelial nitric oxide synthase; NO, nitric oxide; PKC, protein kinase C; PECAM-1, platelet endothelial cell adhesion molecule- 1 (also known as cluster
of differentiation 31); CD99, CD99 antigen (mediating transendothelial migration of human monocytes and lymphocyte recruitment); JAMs, junctional adhesion molecules; VE-cadherin,
vascular endothelial cadherin; ANS, autonomic nervous system; uPAR, urokinase plasminogen activator receptor; CK 1, cytokeratin 1.
Microchannel networks (composed of four successive branching
points and smallest 30 μm square section) have been fabricated using
a soft-lithography technique. The inlet of the microchip has been con-
nected to a fluid reservoir via a silicone tubing, and the outlet to a
1 ml syringe installed on a high precision syringe pump (KDS Legato
110) used in withdraw mode at imposed flow rate. Afterwards, the inner
surfaces of the channels has been coated with fibronectin, and Human
Umbilical Vein Endothelial Cells (HUVECs) were subsequently cultured
within the networks, in the presence of a steady flow of culture medium,
ensuring a physiologically relevant level of fluid shear stress at the wall.
Via this procedure, endothelial cells formed a perfectly confluent mono-
layer on all the walls of the circuit, displaying a glycocalyx that fully
lines the lumen of the microchannels.
After creating a continuous monolayer in the channels, HUVECs’
were stained and subsequently exposed to a constant flow of either cul-
ture medium (control), plasma from healthy volunteer or bradykinin
(Sigma, USA) diluted in endothelial cells culture medium.
Permeability studies were conducted assessing high-affinity interac-
tions between the ligand, fluorescein isothiocyanate-conjugated avidin
(finally added to the perfusion solution) and biotinylated fibronectin
used as a matrix [77].
Images obtained with Laser Scanning Confocal Fluorescence Micro-
scope revealed that no major difference can be detected in fluores-
cence intensity histogram peak or width between the control and the
50%-plasma from healthy volunteer, while in the circuit exposed to
25 μM solution of bradykinin the histogram is clearly shifted to larger
intensity values compared to that obtained for the control. Therefore,
being the microfluidic network able to detect changes of endothelial per-
meability induced by a permeabilizing mediator as bradykinin, the ex-
perimental system seems to be promising to get deeper insights into the
mechanisms underlying HAE as well as other even rarer forms of an-
gioedema [10].
Fig. 2 summarizes the above-mentioned 2D and 2D systems used to
investigate C1-INH-HAE pathophysiology.
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Fig. 2. 2D and 3D methods to assess vascular permeability. (A) Measurements of impedance of endothelial cell monolayers at low AC frequencies (4000 Hz) to evaluate barrier function
changes. The resistive portion of the impedance is used as a parameter for endothelial permeability. An increase in resistance indicates augmented permeability. (B) Transwell perme-
ability assay to measure diffusion of labelled macromolecules through a cell monolayer grown on a porous filter. When permeability increases, a major number of labelled molecules
passes through the membrane in the lower compartment. (C) The Express permeability testing assay (XPerT) for quantification of trans-monolayer permeability. When cellular changes
giving rise to augmented permeability arise, more FITC-conjugated avidin molecules can bind to the biotinylated extracellular matrix resulting in an increase in fluorescence signal. D)
Scheme of a microfluidic three-dimensional device (“microvasculature-on-a-chip”) to assess endothelial permeability. Cell are grown in a microchannel network and are cultured under an
imposed flow rate, subjected to shear stress. Endothelial permeability assessment is based on high-affinity interactions between biotinylated fibronectin used as a matrix for HUVECs and
FITC-conjugated avidin added to the perfusion solution, with confocal microscopy used for cell imaging.
4. In vivo methods to investigate the mechanisms underlying C1-
INH-HAE
4.1. Studies in animal models
In order to investigate the role of C1-INH in vivo and mimic HAE
three different C1-INH knockout mouse models were generated.
In the first model, generated by gene trapping, the Serping1 gene was
targeted into a splice acceptor site in intron 6 (210 bp upstream of exon
7) [32]. Serping1 gene expression is not totally abolished but results
in transcription of a shortened C1-INH variant composed of exons 1–6
fused to construct coded reporter gene (β-geo).
The second one was generated by random mutagenesis, a single base
transition (G to A) at position +1 in the splice donor site of intron 2
caused skipping of exon 2 and a subsequent frame-shift resulting in com-
plete abolition of C1-INH protein synthesis [80].
Finally, for the third one CRISPR/Cas9 technology was used to gen-
erate a C1-INH deficient mouse in which a 10-bp deletion created
a frame-shift causing the introduction of a premature stop codon in exon
3 and the production of a truncated protein consisting of 43 amino acids
[81].
In none of the three models C1-INH protein was detected, neverthe-
less these mice present slightly different phenotypes.
Both the first and third mouse models share a common phenotype;
they present increased vascular permeability of skin and internal organs
and decreased C1-INH and C4 levels. Moreover, similar to human, re-
versal of vascular leakage by treatment with human C1-INH, DX88 (a
plasma kallikrein inhibitor), or the bradykinin B2R antagonist Hoe140
was demonstrated in the first model. However, neither models devel-
oped spontaneous or triggered swelling episodes of skin or organs com-
parable to HAE patients.
Conversely, the second model shows a phenotype closer to HAE pa-
tients. The Serping1-/- mice presented normal vascular permeability un-
der non-stimulated conditions, whereas stimuli such as topical appli-
cation of heparin provoked excessive vascular leakage. Moreover, in-
tradermal injections of heparin and C48/80 (a degranulator of mast
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cells and eosinophils) triggered excessive skin edema that exceeded the
leakage observed in WT mice.
However, none of the mouse models showed spontaneous episodes
of swelling involving the skin or organs as in the human disease.
In general, increased vascular permeability is present in these
C1-INH knockout mice models; although no direct studies on endothe-
lium were performed, its role in vascular leakage is suggested. Han and
coworkers showed a correlation between peripheral vascular permeabil-
ity and the activation of bradykinin B2R, which is constitutively ex-
pressed on endothelial cells [32]. The treatment with the B2R antago-
nist Hoe140 protected the C1-INH KO mice from enhanced vascular per-
meability. Moreover, the double-knockout mice (Serping1-/-, Bdkrb2-/-)
with deficiency of both C1-INH and B2R, showed a diminished vascular
permeability compared to the single C1-INH deficient mice.
Probably a better model to evaluate the role of endothelium in vas-
cular permeability would be a tissue-specific knockout animal in which
B2R is deleted only in endothelial cells.
Recently, a tissue-specific transgenic rat overexpressing the
bradykinin B2R in endothelial cells (B2Rover) was generated using the
vascular endothelial cadherin promoter [82].
Differently from the previous murine models, acute angioedema at-
tacks can be induced in this rat by topical applications of mustard oil.
Moreover, although no skin swelling was observed, intestinal swellings
was present in some animals indicating spontaneous and sporadic occur-
rence of abdominal angioedema.
Another approach used to replicate the C1-INH deficiency associ-
ated with HAE in mouse models is knockdown by the use of antisense
oligonucleotides (ASOs).
Bhattacharjee et al. identified a C1-INH targeted ASO that effectively
reduced C1-INH mRNA expression in the liver and C1-INH plasma pro-
tein levels [83]. Comparably to Serping1-/- mice, C1-INH ASO treated
mice did not exhibit spontaneous swelling events seen in HAE patients
but they showed increased basal vascular permeability as seen in two of
the knockout models.
Besides peripheral vascular permeability, effect of C1-INH depletion
on blood–brain barrier (BBB) integrity and brain function was also in-
vestigated [84].
Circulating C1-INH was knocked down in wild-type mice using ASO,
without affecting its expression in peripheral immune cells or the brain.
Long-term depletion of circulating endogenous C1-INH was shown to
cause neurovascular dysfunction, neuroinflammation, and behavioral
deficits mediated by the activation of the vascular kinin pathway. Al-
though this paper is not directly related to angioedema, the Authors per-
formed investigation on endothelial cells in the brain that could be ap-
plied also to investigate the role of endothelium in angioedema. They
found significant increases in gene expression of B1R and B2R in the
brains of C1-INH ASO-treated mice compared to controls. Moreover, an-
alyzing endothelial cells in the brain they show a decreased expression
of CD31, PECAM1 and occludin, a tight-junction protein that degrades
with increased blood–brain barrier permeability, in the CA1 region of
the hippocampus in C1INH ASO-treated mice.
4.2. Studies in C1-INH-HAE patients
4.2.1. Heart rate variability analysis
When investigating possible triggers or precipitating factors for dif-
ferent kinds of PPDs, it is clear that, while some factors appear to be
detectable more easily, as for instance trauma, surgery or menstrual cy-
cle for C1-INH-HAE or intense physical effort and infections - inflamma-
tory conditions for both C1-INH-HAE and diseases as idiopathic systemic
capillary leak syndrome, others are often reported by patients but their
relationship with recurrences is more complex, as stressful events.
It is known that mental stress, through activation of the sympathoa-
drenal system, activates both coagulation and fibrinolysis [85]
. Given that as above mentioned, the role of fibrinolysis as a general trig-
ger of attacks is emerging [43], the link between stress, hyperfibrinoly-
sis and contact system activation should not be underestimated.
The frequency and severity of angioedema recurrences differ from
patient to patient and in the same patient throughout life. C1-INH
plasma levels do not satisfactorily account for the variability in clinical
phenotypes [19]. In angioedema recurrences, the release of bradykinin
occurs locally and is facilitated by trauma and psychological stress
[86,87]. While it sounds logical to speculate that endothelial cells in-
jured by trauma could become local activators of the contact system,
pathways linking psychological stress to increased endothelial perme-
ability are not obvious [36].
To investigate autonomic nervous system (ANS) modulation in pa-
tients affected by hereditary angioedema due to C1 inhibitor deficiency,
we performed heart rate variability analysis in C1-INH-HAE patients, at
steady state and in a controlled condition of stress induced by the or-
thostatic challenge (tilt testing) [88]. 23 C1-INH-HAE patients during
remission and 24 healthy volunteers were studied.
A three lead-ECG, beat-by-beat plethysmograph arterial blood pres-
sure and respiratory movements were recorded continuously for 10 min
in clinostatism (rest, R) and for 10 min in orthostatism using a head-up
tilt table with a 75° inclination (tilt, T). Autoregressive spectral analy-
sis allowed us to identify the main oscillatory patterns embedded in the
signal: low-frequency (LF, ranging from 0.04 to 0.15 Hz) oscillations,
markers of sympathetic modulation; high-frequency (HF, ranging from
0.15 to 0.4 Hz) component, marker of parasympathetic modulation, syn-
chronous with respiration. Blood samples were collected during rest and
tilt condition to assess C1-INH antigenic and functional levels, C1q and
C4 antigens, cHK and plasma catecholamines.
The results show that mean systolic arterial pressure (SAP) is signifi-
cantly higher in C1-INH-HAE patients than in controls both at R and dur-
ing T. Tilt induced a significant increase in SAP and its variability only
in controls, but not in the HAE patients’ group. LFnu (low-frequency
component, marker of sympathetic modulation, expressed in normal-
ized units) increased significantly after orthostatic challenge both in
C1-INH-HAE patients and in controls, suggesting a preserved response
to the orthostatic challenge. However, only in healthy subjects tilting
induced a significant increase of LF/HF ratio, an index of sympathova-
gal balance. cHK, marker of contact system activation, is increased in
C1-INH-HAE patients compared to controls and tilt test induces a signif-
icant increase in cHK only in C1-INH-HAE patients. Noradrenaline was
higher in patients at R (p = 0.05) and increased in both groups after tilt
test.
Our preliminary results suggest that autonomic modulation is altered
in C1-INH-HAE even during remission periods, with an impairment in
the response to a stressful stimulus. The increase of HK cleavage with
tilt test suggests a link with contact system activation.
A major finding of our study is that patients with C1-INH-HAE, and
no concomitant co-morbidities, have an increased sympathetic modula-
tion at rest, associated with a blunted response to a sympatho-excitatory
stimulus such as head-up tilt. Moreover, tilt test in these patients was
associated with a significant increase in HK cleavage, confirming a cor-
relation between stress and bradykinin production.
4.2.2. Measurement of impaired endothelial function
In order to investigate the impact of hereditary C1-INH deficiency
on atherosclerosis, Demirtürk et al. performed measurement of coronary
flow reserve (CFR) in the left anterior descending coronary artery us-
ing transthoracic doppler harmonic echocardiography at baseline and
following dipyridamole infusion in 26 C1-INH-HAE patients as com-
pared to 30 healthy controls [89]. They demonstrated that the mean
CFR value was significantly lower in the HAE patient group than in
the control group (p < 0.001). Even though no statistically signifi-
cant differences were observed in the intima-media thickness (IMT) in
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the carotid artery between the two study groups, a trend towards higher
values in HAE patients was reported. These findings suggest microvas-
cular early endothelial dysfunction, with development of atherosclerotic
plaques in C1-INH-HAE subjects. However, it should be noted that most
patients were under long term prophylaxis with danazol and this might
have affected the results.
In a recent study Firinu et al. report that the atherosclerotic process
previously revealed in coronary arteries affects also the peripheral ves-
sels in C1-INH-HAE patients [90]. Given the hypothesis that endothe-
lial dysfunction implies an altered response to a variety of patho-phys-
iological stimuli such as reactive hyperemia, the Authors assessed en-
dothelial function by means of non-invasive finger plethysmography
(reactive hyperaemia index: RHI) and levels of asymmetric dimethy-
larginine (ADMA) -which is a strong inhibitor of nitric oxide synthe-
sis- by high-performance liquid chromatography. Their results show that
in C1-INH-HAE patients RHI was lower (2.03 ± 0.46 vs. 2.82 ± 0.34,
p < 0.0001) and ADMA higher (0.636 ± 7 vs. 585 ± 5 micromol/
L, p < 0.01) than in controls. There was a statistically significant in-
verse correlation between RHI and patients’ ADMA levels (r = − 0.516,
p = 0.009). No statistically significant differences were observed be-
tween C1-INH-HAE and FXII-HAE subgroups. Interestingly, these pa-
tients were studied during the attack-free period and none of them was
under attenuated androgens (a factor which could have shifted the lipid
profile to a pro-atherogenic phenotype). No significant correlations were
detected between RHI and gender, age at disease onset, disease duration
and severity scores (all p = ns).
These results cast new light on the role of bradykinin in ADMA
production, through stimulation of B2 receptors, stimulation of nicoti-
namide adenine dinucleotide phosphate (NADPH) oxidases and produc-
tion of reactive oxygen species (ROS) or reduction of dimethylarginine
dimethylaminohydrolase activity.
However, the topic is still controversial and Nebenfuhrer et al. in a
very recent study report no signs of endothelial dysfunction in HAE pa-
tients [91]. They performed ultrasound assessment of endothelium-de-
pendent flow-mediated dilation of the brachial artery in 33 C1-INH-HAE
patients and in 30 healthy matched controls. No difference was found
in endothelial function (reactive hyperemia, RH) between patients (me-
dian, 9.0; 25–75%percentile, 6.3–12.9) and controls (median, 7.37;
25–75%percentile, 4.52–9.93). Moreover, no alterations were detected
in danazol-treated patients. They could not find significant differences in
RH values of patients with low and high attack frequency. Surprisingly,
in C1-INH-HAE patients no differences were found in the RH values of
smokers and non smokers and the correlation between the RH levels and
the LDL-C/HDL-C ratio or FMD and FRS was detected only in the dana-
zol-non treated subgroup.
Therefore, the Authors speculate that bradykinin may have a cardio-
protective role, through production of nitric oxide and prostaglandin I2
(prostacyclin), which have vasodilating, anti-thrombotic and inflamma-
tion-modulating effects.
However, the Authors themselves admit that the lower age of pa-
tients enrolled in the study (as compared to previous studies) might have
affected the results.
Further studies are needed to investigate endothelial dysfunction in
HAE patients.
4.2.3. Nailfold videocapillaroscopy
Paralleling studies performed in connective tissue diseases, nail-
fold videocapillaroscopy (NVC) has recently been applied to investi-
gate structural alterations of the microvasculature in C1-INH-HAE pa-
tients [92]. Cesoni Marcelli et al. enrolled twenty-eight C1-INH-HAE pa-
tients (mean age 35 years [8–73];14 male) in remission, ten patients
with ACE-I-AE (mean age 67 years [46–76]; 7 male) and thirty-eight
controls. NVC was performed, evaluating the following features: capil
lary morphology, distribution, density and length; intercapillary dis-
tance; apical, internal and external diameter.
Interestingly, the results showed that C1-INH-HAE patients had in-
creased apical, internal and external diameter compared to controls
(28 [23–40] vs 22 [16–29] μm median values (interquartile ranges),
p < 0.01; 23 [20–27] vs 20 [18–22] μm, p < 0.01; 81 [70–89] vs65
[55–73] μm, p < 0.001, respectively). The capillary density was de-
creased in patients as compared to controls (4/mm [4–5] vs5/mm
[5–6], p < 0.001). C1-INH-HAE patients had a higher prevalence of
alterations in capillary distribution as compared to controls (irregu-
lar vs ordered, p < 0.01). Moreover, a positive correlation was found
between internal and apical diameter (p < 0.05), external and api-
cal (p < 0.0001) and external and internal diameter (p < 0.05), while
capillary density was negatively correlated with apical diameter
(p < 0.05). No differences were found in capillary morphology and
length and intercapillary distance. NVC did not highlight any significant
microvascular alteration in ACE-I-AE patients as compared to controls.
NVC performed in two C1-INH-HAE patients during acute attacks in-
volving the hands and the abdomen detected no changes compared to
the remission phase.
Therefore, microvascular structural alterations found in C1-INH-HAE
seem to be a constant feature (not related either to acute/ remission
phase or to site of the attack) and they could play a role which is not
negligible in angioedema pathogenesis.
5. Discussion
Hereditary angioedema due to C1 inhibitor deficiency is undeniably
the paradigm of Paroxysmal Permeability Disorders, conditions charac-
terized by recurrent episodes of increased vascular permeability which
has a transient nature and is usually self-limiting, but can be extremely
dangerous in certain circumstances, as when the upper airways are in-
volved (with the risk of death due to asphyxia) or when the clinical pic-
ture of abdominal acute attacks leads to unnecessary surgery.
Starting from the very first description of the disease in 1888 and
from the identification of C1 inhibitor deficiency in 1963, knowledge
about this condition has expanded remarkably over the years, leading
to the possibility to design more and more drugs and to tailor patients’
treatment with an individualized perspective. The present review under-
lines the crucial role of the endothelium in the pathophysiology of this
disease: the endothelium is not just a passive bystander which is the
target of action of ever increasing identified possible mediators; the en-
dothelium is rather an active player, whose stability-instability is deter-
mined by an ever changing bi-directional interplay with the surround-
ing environment, characterized by constant exposure to flow and related
shear stress and integration in a complex living organism, with all re-
lated modulators (as autonomic nervous system modulation of cardio-
vascular activity).
Awareness of the above-mentioned complexity can help elaborat-
ing hypotheses on the most intriguing yet challenging topics related to
C1-INH-HAE.
The first one regards the localized nature of acute C1-INH-HAE at-
tacks. A question which is still unanswered is whether swelling involv-
ing a specific site should be regarded as the local expression of a sys-
temic derangement or not [93]. With this regard, some evidence exists
about local generation of bradykinin, with possible local activation of
the kinin-releasing system by rarely identified triggers (physical trauma,
oral surgery. etc), as demonstrated by higher BK levels in the venous
compartment of the affected limb as compared to those of the unaffected
limb [86]. This is consistent with the usual absence of hypotension dur-
ing HAE attacks.
On the other hand, the localized nature of angioedema attacks de-
spite a systemic activation of the CAS/KKS might be supported by
the following considerations: endothelial cells are intrinsically differ-
ent from site to site, they may gain a local activation status and a sort
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of priming (sometimes due to or exacerbated by specific local triggers)
because of exposure to specific mediators (as Angpt2 and VEGF), to ex-
pression/upregulation of inducible receptors (as bradykinin B1 recep-
tor), to local alterations of the glycocalyx, interendothelial cell junctions
and activation of specific intracellular pathways. Interestingly, since
bradykinin B2 receptor is rapidly desensitized after interaction with BK,
while B1Rs are expressed longer on endothelial cells after induction
[94], expression of B1Rs in specific sites has been envisaged as a pivotal
mechanism explaining the localized nature of attacks. However, efficacy
of icatibant, antagonist of the B2R, in reverting the hyperpermeability
state should be taken into consideration and the role of constitutively
expressed B2R cannot be underestimated.
The systemic hypothesis is corroborated by the finding of increased
values of activation products (as cHK) in plasma samples from
C1-INH-HAE patients as well as by attacks involving multiple sites. The
presence of prodromal signs and symptoms in some cases also suggests
a systemic process [46].
The priming of endothelial cells, chronically exposed to hyperperme-
abilizing factors even during the intercritical periods, and the complex-
ity of the mechanisms activated to answer to a high variety of stimuli
(and possibly inability to adapt to ever changing conditions) might sup-
port the threshold hypothesis, according to which C1-NH-HAE patients
do carry a stable deficiency which makes them more prone to develop
hyperpermeability and this lower threshold for edema formation is eas-
ily overcome episodically when a wide spectrum of possible factors in-
teract one with another. This issue may help explaining the episodic na-
ture of acute attacks despite a constant underlying deficit as well as the
reasons why the disease shows an unpredictable pattern of attacks re-
currence, both among affected family members and in the very same pa-
tient in different periods of life.
The seek for biomarkers is ongoing, but caution is warranted, given
that, as some Authors have underlined, for most of the proposed bio-
markers a causality correlation has not been proven so far [95].
In vitro studies have helped acquiring many of the currently shared
notions about the pathogenesis of angioedema. However, it should be
underlined that cautious selection of endothelial cells used in in vitro es-
says is of pivotal importance: the phenotype of endothelial cells differs
substantially from one vascular bed to another one. Since angioedema
episodes occur preferentially in the skin, in some papers, endothelial
cells were also isolated from human adult dermal microvasculature (AD-
MECs) rather than from the umbilical vein (HUVECs). Alternatively,
cells can be obtained from commercial suppliers that offer arterial, ve-
nous or microvascular endothelial cells from different organs. To avoid
an influence of individual variability, pooling cells from four-five donors
is recommended. With division/passage number primary endothelial
cells tend to differentiate and loose some functions, including the ability
to induce oxidative stress etc. Therefore, endothelial cell lines are not
recommended since classical physiology could be missing.
Endothelial cells in culture downregulate a number of genes that are
expressed in situ, since in most cell culture systems shear stress, which is
able to up regulate several genes, is missing. Three dimensional models
with endothelial cells continuously exposed to physiological flow condi-
tions are undeniably promising tools to overcome these limitations. Pre-
liminary results with exposure to bradykinin are promising and open the
way to many possible further investigations, last but not least the possi-
bility to test drugs and their delivery.
New techniques as HRV analysis, nailfold capillaroscopy, non-in-
vasive finger plethysmography and reactive-hyperemia-based methods
may help to shed more light on the mechanisms underlying angioedema,
hopefully giving new insights that may help also to better individualize
therapy not only in C1-INH-HAE but also in other types of angioedema.
Finally, we also speculate that C1-INH-HAE may serve as useful
model to understand endothelial behaviour in a wide spectrum of clini
cal conditions.
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